Drug Discovery Market Size
| Study Period | 2020 - 2029 |
| Market Size (2024) | USD 100.10 Billion |
| Market Size (2029) | USD 137.72 Billion |
| CAGR (2024 - 2029) | 6.59 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Drug Discovery Market Analysis
The Drug Discovery Market size is estimated at USD 100.10 billion in 2024, and is expected to reach USD 137.72 billion by 2029, growing at a CAGR of 6.59% during the forecast period (2024-2029).
Amid the COVID-19 pandemic, the health systems of various countries rapidly invested in research and development to combat the virus. Potential compounds were screened from the CHEMBL, ZINC, FDA-approved drugs, and molecules under clinical trials. Research groups worldwide have identified drugs for the treatment of COVID-19 by screening both novel and existing drugs for their ability to alleviate symptoms and stop viral replication. Thus, the drug discovery market was positively impacted due to the urge to find a cure for COVID-19. Furthermore, post the pandemic, there is a rise in investments in different modalities of drug development, such as gene and cell therapies for both COVID-19 diseases and other novel diseases, which is expected to impact the market's growth as per the analysis positively. Furthermore, the research for developing antiviral drugs for COVID-19 is still in progress. For instance, in May 2022, the National Institute of Allergy and Infectious Diseases (NIAID) awarded approximately USD 577 million to establish nine Antiviral Drug Discovery (AViDD) Centers for Pathogens of Pandemic Concern. The AViDD centers will carry out creative, interdisciplinary research to create candidate COVID-19 antivirals, particularly those that can be used outside of a hospital setting, as well as antivirals that target particular viral families with a high potential to trigger a pandemic in the future. Such grants are expected to drive the drug discovery market's growth post-pandemic.
The propelling factors for the growth of the drug discovery market include the rising burden of a wide range of diseases (such as cardiovascular and CNS-related disorders), rising healthcare expenditure, and the upcoming patent expiration of blockbuster drugs.
Cardiovascular diseases, infectious diseases, diabetes, and kidney-related complications are highly prevalent worldwide. According to key facts about cardiovascular diseases (CVDs) published by the WHO in June 2021, CVDs are the leading cause of death globally, representing around 32% of all global deaths. CVD remains the leading cause of death and disability and remains highly complicated, costly, and burdensome. Moreover, new strategies are required to streamline and reduce the costs of clinical trials while placing greater importance on the patient experience and voice. Thus, the increasing burden of a diverse range of diseases among all age groups and its burden globally drive the demand for drug discovery and its market.
Furthermore, there has been an upsurge in the usage of advanced technologies, such as high-throughput process development, bioinformatics, and combinatorial chemistry, for better drug candidate identification. Drug discovery has evolved significantly with emerging technologies, helping the process become more refined, accurate, and time-efficient. The adoption of artificial intelligence systems in disease diagnostics and treatment design is growing, and this is expected to witness robust growth in the coming years. For instance, in March 2020, Existencia, an AI-based drug discovery company, entered a collaborative agreement with Diamond Light Source and Scripps Research to identify COVID-19 antiviral therapies. Thus, these factors are anticipated to contribute to the market's growth over the forecast period.
However, the huge capital investment, low-profit margins, and stringent drug discovery regulations are expected to hinder the market growth.
Drug Discovery Market Trends
Biologics Drug Segment is Expected to Show a Significant Growth Over the Forecast Period.
During the pandemic, the rising adoption of biologics due to their specific advantages, especially target specificity, bodes well for the market studied. As a result, many major biotech firms are in the middle of a race to investigate the SARS-CoV-2 genome and prepare therapeutics. Furthermore, COVID-19 has significantly impacted the growth of biologics due to the rise in the development of biologics for SARS-CoV-2. For instance, in February 2022, AbCellera launched bebtelovimab (LY-CoV1404), the second antibody developed through AbCellera's collaboration with Eli Lilly and Company (Lilly), which has received Emergency Use Authorization from the FDA for the treatment of mild to moderate COVID-19.
Biologic drugs offer several benefits, such as highly effective and potent action, fewer side effects, and the potential to cure diseases rather than merely treat the symptoms, significantly increasing the demand for these products.
The efficacy and safety of biologics have led to their rapid adoption by people, driving the growth of the biologics segment. This has led to an increase in partnerships among drug discovery companies for the development of biologics. For instance, in August 2022, Sanofi and Innovent Biologics entered a strategic collaboration to accelerate the development of oncology medicines and expand their presence in China. In addition, in February 2022, Abzena, Alira Health, and Oncodesign launched DRIVE biologics. These companies are entering a consortium to offer their partners synergy and expertise in biologics drug discovery and development programs. Such partnerships are expected to drive the growth of this segment due to the rise in the development and adoption of biologics for various diseases over the forecast period.
Moreover, the rise in approvals for biologics from international regulatory agencies is further expected to propel the growth of this segment. For instance, in February 2022, the FDA accepted for review the Prior Approval Supplement (PAS) to the Biologics License Application (BLA) for ABRILADA (adalimumab-afzb) as an interchangeable biosimilar to Humira (adalimumab). Such initiatives are expected to drive the growth of the biologics segment.
Therefore, owing to the above-mentioned factors, the biologics segment is expected to experience tremendous growth.
North America is Expected to Hold a Significant Market Share Over the Forecast Period
North America has a significant share of the world's R&D spending on pharmaceuticals and biologics. The factors contributing to the growth of this region include a rise in investments by drug development companies, huge grants from the government of the United States, a strong foothold of major drug development companies, well-developed healthcare infrastructure, and a rise in chronic diseases, among others.
For instance, according to the ACS "Cancer Facts & Figures 2022," around 1,918,030 new cancer cases and 609,360 deaths due to cancer are estimated to be reported in the United States by the end of 2022. Such a high incidence of cancer in this region is anticipated to drive drug discovery for cancer, driving the market growth.
Furthermore, the rise in technological advancements in drug discovery in the United States is expected to drive the drug discovery market in this region. For instance, in September 2022, CytoReason entered a multi-year partnership with Pfizer to use CytoReason's artificial intelligence technology for Pfizer's drug development program. Such collaborations among key market players in the United States to implement AI technology in drug discovery are expected to drive the growth of this market studied in this region.
Therefore, owing to the above-mentioned factors, the drug discovery market is expected to increase over the forecast period.
Drug Discovery Industry Overview
The drug discovery market is highly competitive and consists of a number of major players. The market players are implementing innovative strategies and adopting artificial intelligence and machine learning in drug discovery to speed up the process. Furthermore, the key market players are entering into strategic partnerships to develop novel drug molecules. Some of the companies in this market include Eli Lilly and Company, Novartis AG, Bayer AG, AbbVie Inc., AstraZeneca PLC, F. Hoffmann-La Roche Ltd., Pfizer Inc., and Sanofi.
Drug Discovery Market Leaders
-
Eli Lilly and Company
-
Bristol-Myers Squibb Company
-
Novartis AG
-
Bayer AG
-
AbbVie Inc.
*Disclaimer: Major Players sorted in no particular order
Drug Discovery Market News
- October 2022: Verge Genomics, a clinical-stage and technology-enabled biotechnology company pioneering the use of artificial intelligence (AI) and human data to transform drug discovery, announced dosing the first subject in its Phase 1 clinical trial of VRG50635.
- October 2022: NGM Bio released topline results from the CATALINA Phase 2 Trial of NGM621 in patients with geographic atrophy (GA) secondary to age-related macular degeneration.
Drug Discovery Market Report - Table of Contents
1. INTRODUCTION
- 1.1 Study Assumptions and Market Definition
- 1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
- 4.1 Market Overview
-
4.2 Market Drivers
- 4.2.1 Rising Burden of Various Chronic Diseases
- 4.2.2 Increasing R&D Expenditure and Investment in the Development of Novel Drug Molecules
-
4.3 Market Restraints
- 4.3.1 Huge Capital Investment with Low Profit Margins
- 4.3.2 Stringent Government Regulations
-
4.4 Porter's Five Forces Analysis
- 4.4.1 Threat of New Entrants
- 4.4.2 Bargaining Power of Buyers/Consumers
- 4.4.3 Bargaining Power of Suppliers
- 4.4.4 Threat of Substitute Products
- 4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD Million)
-
5.1 Drug Type
- 5.1.1 Small Molecule Drugs
- 5.1.2 Biologic Drugs
-
5.2 Technology
- 5.2.1 High Throughput Screening
- 5.2.2 Pharmacogenomics
- 5.2.3 Combinatorial Chemistry
- 5.2.4 Nanotechnology
- 5.2.5 Other Technologies
-
5.3 End User
- 5.3.1 Pharmaceutical Companies
- 5.3.2 Contract Research Organizations (CROs)
- 5.3.3 Other End Users
-
5.4 Geography
- 5.4.1 North America
- 5.4.1.1 United States
- 5.4.1.2 Canada
- 5.4.1.3 Mexico
- 5.4.2 Europe
- 5.4.2.1 United Kingdom
- 5.4.2.2 Germany
- 5.4.2.3 France
- 5.4.2.4 Italy
- 5.4.2.5 Spain
- 5.4.2.6 Rest of Europe
- 5.4.3 Asia-Pacific
- 5.4.3.1 China
- 5.4.3.2 Japan
- 5.4.3.3 India
- 5.4.3.4 Australia
- 5.4.3.5 South Korea
- 5.4.3.6 Rest of Asia-Pacific
- 5.4.4 Middle East and Africa
- 5.4.4.1 GCC
- 5.4.4.2 South Africa
- 5.4.4.3 Rest of Middle East and Africa
- 5.4.5 South America
- 5.4.5.1 Brazil
- 5.4.5.2 Argentina
- 5.4.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
-
6.1 Company Profiles
- 6.1.1 AbbVie Inc.
- 6.1.2 Bristol-Myers Squibb Company
- 6.1.3 AstraZeneca PLC
- 6.1.4 Bayer AG
- 6.1.5 Eli Lilly and Company
- 6.1.6 F. Hoffmann-La Roche Ltd
- 6.1.7 GlaxoSmithKline PLC
- 6.1.8 Merck & Co. Inc.
- 6.1.9 Novartis
- 6.1.10 Pfizer Inc.
- 6.1.11 Takeda Pharmaceuticals
- 6.1.12 Sanofi
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
** Subject To AvailablityDrug Discovery Industry Segmentation
As per the scope of the report, drug discovery is a process aimed at identifying a compound that is therapeutically useful in treating and curing diseases. Typically, a drug discovery effort addresses a biological target that has been shown to play a role in the development of the disease or starts from a molecule with interesting biological activities. In the recent past, drug discovery has evolved significantly with emerging technologies, helping the process become more refined, accurate, and time-consuming.
The drug discovery market is segmented by drug type (small molecule drugs and biologic drugs), technology (high throughput screening, pharmacogenomics, combinatorial chemistry, nanotechnology, and other technologies), end user (pharmaceutical companies, contract research organizations (CROs), and other end users), and geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The report offers market forecasts and revenues in terms of value in USD million for the above segments.
| Drug Type | Small Molecule Drugs | |
| Biologic Drugs | ||
| Technology | High Throughput Screening | |
| Pharmacogenomics | ||
| Combinatorial Chemistry | ||
| Nanotechnology | ||
| Other Technologies | ||
| End User | Pharmaceutical Companies | |
| Contract Research Organizations (CROs) | ||
| Other End Users | ||
| Geography | North America | United States |
| Canada | ||
| Mexico | ||
| Geography | Europe | United Kingdom |
| Germany | ||
| France | ||
| Italy | ||
| Spain | ||
| Rest of Europe | ||
| Geography | Asia-Pacific | China |
| Japan | ||
| India | ||
| Australia | ||
| South Korea | ||
| Rest of Asia-Pacific | ||
| Geography | Middle East and Africa | GCC |
| South Africa | ||
| Rest of Middle East and Africa | ||
| Geography | South America | Brazil |
| Argentina | ||
| Rest of South America |
Drug Discovery Market Research FAQs
How big is the Drug Discovery Market?
The Drug Discovery Market size is expected to reach USD 100.10 billion in 2024 and grow at a CAGR of 6.59% to reach USD 137.72 billion by 2029.
What is the current Drug Discovery Market size?
In 2024, the Drug Discovery Market size is expected to reach USD 100.10 billion.
Who are the key players in Drug Discovery Market?
Eli Lilly and Company, Bristol-Myers Squibb Company, Novartis AG, Bayer AG and AbbVie Inc. are the major companies operating in the Drug Discovery Market.
Which is the fastest growing region in Drug Discovery Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Drug Discovery Market?
In 2024, the North America accounts for the largest market share in Drug Discovery Market.
What years does this Drug Discovery Market cover, and what was the market size in 2023?
In 2023, the Drug Discovery Market size was estimated at USD 93.50 billion. The report covers the Drug Discovery Market historical market size for years: 2020, 2021, 2022 and 2023. The report also forecasts the Drug Discovery Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
What are the key factors driving the Drug Discovery Market?
The Drug Discovery Market is driven by a) The increasing adoption of biologics b) The development of novel drug molecules.
Drug Discovery Industry Report
The Global Drug Discovery Market is segmented by drug type, technology, end user, and geography. The market report offers a detailed analysis of key market drivers and market segments, providing market forecasts and revenues in terms of value. The industry analysis includes segments such as small molecule drugs and biologic drugs, with technologies like high throughput screening, pharmacogenomics, combinatorial chemistry, and nanotechnology. End users include pharmaceutical companies, contract research organizations, and other end users.
The market overview highlights the growth rate and market size, with a focus on the global market. The market report provides insights into the market forecast and market growth, offering an industry outlook that covers the industry profile and industry trends. The industry research includes market segmentation and market value, providing a comprehensive understanding of the market data and market predictions.
The report also includes industry information, industry reports, and industry statistics, giving a thorough market review. The market leaders and market outlook are discussed, along with market segmentation and market value. The report example and report pdf are available for further details. Research companies and industry sales are also covered, providing a complete picture of the market trends and market overview.
